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STATE OF THE ART: CONCISE REVIEW
Abstract: Lung cancer is a common disease with more than 1.6 mil-
lion new cases diagnosed worldwide in 2008. Treatments for patients 
with advanced disease are rarely curative, and responses to therapy are 
often followed by relapse, which highlights the large unmet need for 
novel therapies. Recent advances in cancer treatment have focused on 
personalized therapy, whereby patients are treated with agents that best 
target the molecular drivers of their disease. Thus, a better understand-
ing of the pathways that drive cancer or drug resistance is of critical 
importance. One such example is the phosphatidylinositol 3-kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which 
is activated in many lung cancer patients and represents a target for 
therapy. PI3K/AKT/mTOR pathway activation has also been observed 
in tumors resistant to agents targeting upstream receptor tyrosine 
kinases. Agents that target this pathway have the potential to shut down 
survival pathways, and are being explored both in the setting of path-
way-activating mutations and for their ability to restore sensitivity to 
upstream signaling targeted agents. Here, we examine the frequency of 
mutations activating the PI3K/AKT/mTOR pathway, review the novel 
agents being explored to target this pathway, and explore the potential 
role of the inhibition of this pathway in the clinical development of 
these agents.
Key Words: PI3K/AKT/mTOR pathway, Personalized medicine, 
Non–small cell lung cancer.
(J Thorac Oncol. 2012;7: 1315–1326)
Cancer treatment is in the midst of a revolution toward personalized therapy. As the mechanisms that drive can-
cer are deciphered, agents targeting the affected pathways are 
developed. These discoveries and advances allow patients to 
be treated with agents that best target the molecular elements 
that drive their disease, potentially offering higher response 
rates and improvements in survival. Historical examples 
include the antihuman epidermal growth factor receptor 2 
(HER2) agents in HER2-overexpressing breast cancer1 and 
epidermal growth factor receptor (EGFR)- and anaplastic 
lymphoma kinase (ALK)-targeted agents in non–small-cell 
lung cancer (NSCLC).2,3
Lung cancer, presenting as metastatic disease in the 
majority of cases, is responsible for 87,750 deaths (29% of 
cancer deaths) in men and 72,590 deaths (26% of cancer 
deaths) in women yearly in the United States.4 Despite modest 
improvement in survival with the addition of bevacizumab to 
platinum-based therapy the treatment of metastatic lung can-
cer is an area of unmet need.5 Recent advances in molecular 
profiling have identified the mutations and aberrations that 
drive many NSCLCs, thereby enabling a personalized medi-
cine approach to treatment. Many of these mutations affect 
the phosphatidylinositol 3-kinase/AKT/mammalian target of 
rapamycin (PI3K/AKT/mTOR) pathway—a key regulator of 
many cellular processes, including cell survival, prolifera-
tion, and differentiation.6 This review focuses on the muta-
tions associated with PI3K/AKT/mTOR pathway activation 
in NSCLC, the novel agents that target these mutations, and 
the clinical development opportunities for PI3K/AKT/mTOR 
pathway inhibition.
PI3K/AKT/mTOR PATHWAY
Signaling in the PI3K/AKT/mTOR pathway, which has 
been extensively reviewed previously7–9 (Fig. 1), is initiated 
by the binding of extracellular growth factors to transmem-
brane receptor tyrosine kinases (RTKs), including EGFR, 
HER2, insulin-like growth factor receptor, vascular endothe-
lial growth factor receptor, and platelet-derived growth factor 
receptor. Upon ligand binding, the RTKs become activated 
and recruit PI3K to the plasma membrane. There are three 
classes of PI3Ks, and the class IA PI3K is the most frequently 
implicated in human cancer.
Class IA PI3Ks are heterodimeric and consist of a 
p110 catalytic subunit and a p85 regulatory subunit, which 
inhibit p110 in the absence of RTK activation by ligand. There 
are three p110 isoforms for class IA PI3Ks: p110, p110, 
and p110, which are encoded by PIK3CA, PIK3CB, and 
PIK3CD, respectively. Upon ligand binding and RTK phos-
phorylation, p85 binds the RTK and frees the catalytically 
active p110 subunit, enabling its localization to the plasma 
membrane. Here, it catalyzes the phosphorylation of phospha-
tidylinositol 4,5-bisphosphate (PIP
2
) to phosphatidylinositol 
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3,4,5-triphosphate (PIP
3
). PIP
3
 localizes AKT to the plasma 
membrane to allow phosphorylation by 3-phosphoinositide-
dependent kinase 1. A second phosphorylation by the mTOR 
complex 2 (mTORC2) provides full activation of AKT. Once 
phosphorylated, AKT dissociates from the plasma membrane 
and is capable of phosphorylating 100 and more of its targets 
in the nucleus and cytoplasm. These targets include tuberous 
sclerosis 2 (which leads to mTOR complex 1 [mTORC1] acti-
vation), murine double minute 2, forkhead box O, and Bcl-
2-associated death promoter. Together, activation of these 
targets leads to increased cell growth, metabolism, survival, 
and proliferation.
Multiple components of the PI3K/AKT/mTOR pathway 
are involved in the control of oncogenic growth, and multiple 
loops of negative regulation exist. For example, Src homology 
2 domain-containing inositol 5-phosphatase and the tumor-
suppressor phosphatase and tensin homolog (PTEN) dephos-
phorylate PIP
3
 to the inactive PIP
2
 and thereby attenuate AKT 
activation. Further conversion of PIP
2
 to PIP is mediated by 
the tumor-suppressor inositol polyphosphate-4-phosphatase, 
type II.10 Another negative feedback loop is mediated by S6 
kinase, a target of mTORC1, which can inhibit the adaptor 
molecule insulin receptor substrate 1, which thereby prevents 
the activation of PI3K by insulin growth factor 1.11
The PI3K/AKT/mTOR pathway interacts with other par-
allel signaling cascades, such as the Rat sarcoma (RAS)/rap-
idly accelerated fibrosarcoma (RAF)/mitogen-activated protein 
kinase or Erk kinase (MEK) pathway. For example, RAS, the 
major upstream component of this pathway, can also directly 
activate class IA PI3K (Fig. 1). Given its central role, it is 
predictable that disruption of the PI3K/AKT/mTOR pathway 
affects tightly regulated cellular processes. Unsurprisingly, it is 
one of the most commonly deregulated pathways in cancer.8,12,13
PI3K/AKT/mTOR PATHWAY MUTATIONS  
IN NSCLC
On the basis of AKT phosphorylation, the PI3K pathway 
is active in 50% to 70% of NSCLCs,14–16 and pathway activation 
confers a poor prognosis.17,18 Activation could result from muta-
tions or alterations throughout this or parallel pathways (e.g., 
KRAS and EGFR), leading to increased cell survival, prolif-
eration, and differentiation. For example, mutations in RAS, or 
those that cause constitutive activation of PI3K, AKT, such as 
the AKT1 E17K mutation,19 or upstream RTKs, can drive can-
cers in a ligand-independent fashion.20 Mutations that inactivate 
the negative regulator PTEN have also been observed.21 More 
common, however, is the observation of reduced or absent 
PTEN expression in NSCLC. Indeed, the high frequency of 
FIGURE 1.  The PI3K/AKT/mTOR pathway. Extrinsic binding and subsequent activation of extracellular growth factors to 
transmembrane receptor tyrosine kinases induce PI3K recruitment to the plasma membrane. Once there, the PI3K subunit 
p110 catalyzes the phosphorylation of PIP2 to PIP3. PIP3 localizes AKT to the plasma membrane, where it gets phosphorylated 
by 3-phosphoinositide-dependent kinase 1 . After a second phosphorylation event by mTOR complex 2, the fully activated AKT 
dissociates from the plasma membrane and activates targets that drive increased cell growth, metabolism, survival, and prolifera-
tion. The pathway is negatively regulated by the tumor-suppressor phosphatase and tensin homolog, which dephosphorylates 
PIP3 to the inactive PIP2, which can then be further dephosphorylated to PIP by inositol polyphosphate-4-phosphatase, type II. 
Another attenuation mechanism is mediated by S6 kinase-mediated inhibition of the adaptor molecule insulin receptor substrate 
1. Cross-talk between the parallel RAS/mitogen-activated protein kinase/ERK and PI3K/AKT/mTOR pathways can also take place 
via direct activation of PI3K by RAS. Other links to parallel pathways include mTOR complex 1 activation via ERK inhibition of 
tuberous sclerosis 2 and RAF inactivation by phosphorylated AKT. PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target 
of rapamycin; RAS, Rat sarcoma; PIP2 , phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-triphosphate; ERK, 
extracellular signal-regulated kinase.
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PTEN loss (~45%), coupled with an additional 29% of tumors 
showing reduced PTEN protein expression, suggests a role 
of PTEN inactivation in NSCLC tumorigenesis.17,22 Although 
loss of heterozygosity at microsatellites in chromosome 10q23 
surrounding and intragenic to the PTEN locus and hypermeth-
ylation of the PTEN gene are commonly observed (19% and 
26%, respectively), they are not predictors of protein expres-
sion.22 Research continues to elucidate potential transcriptional 
and translational explanations.
Not all of the large number of mutations that can 
affect the PI3K/AKT/mTOR pathway have been observed 
in NSCLC. As shown in Table 1, the frequency of each 
mutation can also vary by histology.23 KRAS and EGFR 
kinase domain mutations are rare in squamous cell carci-
noma (SCC); however, KRAS mutations occur in 20% to 
30% of adenocarcinomas,24 and EGFR mutations in 10% 
to 20%, with a higher incidence in patients of Asian origin. 
Conversely, EGFR expression and PIK3CA amplifica-
tions are more common in SCC than in adenocarcinoma. 
The presence of these mutations may predict the outcome 
of targeted therapy, and several of the molecular altera-
tions implicated in the PI3K/AKT/mTOR pathway may 
also provide prognostic information. For example, EGFR-
activating mutations indicate a favorable prognosis,25,26 
whereas increases in mesenchymal epithelial transition 
factor (MET) copy number27,28 and a loss of PTEN expres-
sion indicate a poor prognosis.17
RATIONALE AND PRECLINICAL DATA FOR 
TARGETING THE PI3K/AKT/mTOR  
PATHWAY IN NSCLC
The ability to target the molecular drivers of PI3K/
AKT/mTOR activation using pathway-specific inhibitors is 
currently being explored in NSCLC. These studies are being 
supported by preclinical observations. There are at least three 
settings in which these agents may be useful: (a) reversal of 
resistance to upstream RTK-targeted therapy, (b) PI3K/AKT/
mTOR pathway mutations, and (c) parallel pathway activation.
Mutations in RTKs
The RTKs represent an entry point to PI3K/AKT/
mTOR pathway activation. As seen in Table 1, mutation 
or amplification of RTKs has been observed in NSCLC, 
which leads to ligand-independent signaling. Therefore, 
agents that target the PI3K/AKT/mTOR pathway could be 
used to suppress these signals. For example, EGFR is over-
expressed in up to 60% of patients with NSCLC, but not 
all of these patients respond to the EGFR-tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib, and eventually all 
patients who experience tumor response will have disease 
TABLE 1.  Frequency of Mutations Affecting the PI3K/AKT/mTOR Pathway
Squamous (%)
NonSquamous
Total (%) Reference
Adenocarcinoma 
(%)
Large Cell 
(%)
Receptor tyrosine kinases
 EGFR Mutation 5 12–20 3–9 15–20 (up to 60 Asians) 25,26,111–115
Increased copy 
number
UNK 41 UNK 29–40 26,43,111,112,116,117
 ALK Mutation 5 1 7 2 115
Rearrangement 
(EML4-ALK)
1 3–7 UNK 2–7 36–38,115,118–120
 MET Mutation 1 2 UNK 2–14 23,27,115,121
Amplification 21 20 UNK 2–21 (higher frequency in patients 
with acquired resistance to TKIs)
27,28,43,44,122–124
RAS/RAF/MEK pathway components
 KRAS Mutation 6–9 12–53 18 8–21 25,26,111,115,125
PI3K/AKT/mTOR pathway components
 PTEN Mutation 6 1 3 4–5 115,126
Loss/reduction Loss/ 
reduction: 70
Loss/ 
reduction: 77
Loss/ 
reduction: 62
Loss: 24–44; reduction: 29–46
Promoter hypermethylation at 
PTEN: 26, at PTENP1: 66
22,26,45
 PIK3CA Mutation 2–7 2 3 2–5 115,126–130
Amplification 33–70 6–19 38 12–20 126,130–134
 LKB1 Mutation 27 33–54 43 9–33 53,135–138
 AKT1 Mutation 
(E17K)
1 <1 UNK 1–2 19,115,139,140
UNK, unknown; EGFR, epidermal growth factor receptor; EML4, echinoderm microtubule-associated protein-like 4; MET, mesenchymal epithelial transition factor; RAS, rat 
sarcoma; MEK, mitogen-activated protein kinase or Erk kinase; PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog; 
LKB1, liver kinase B1.
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progression—often because of downstream PI3K/AKT/mTOR 
pathway activation.29,30 Studies have shown, however, that the 
combination of PI3K inhibitors with EGFR-TKIs or mono-
clonal antibodies can inhibit viability in cell lines resistant 
to EGFR-TKIs or monoclonal antibodies.31–35 These data sup-
port the prospect of using PI3K/AKT/mTOR pathway inhibi-
tors to restore sensitivity to EGFR-TKIs in resistant tumors. 
Furthermore, molecular profiling of EGFR-TKI–resistant 
tumors may help identify those patients who would benefit 
most from PI3K/AKT/mTOR inhibition.
Fusions of the RTK ALK to echinoderm microtubule-
associated protein-like 4 lead to constitutive activation of the 
kinase in NSCLC.36–38 These patients can be treated with the 
recently approved ALK/MET inhibitor crizotinib; however, a 
number of crizotinib-resistant mutants have already been iden-
tified.39,40 Of note, resistance to MET inhibition by crizotinib 
can lead to activation of the PI3K/AKT/mTOR pathway, as 
demonstrated in a gastric carcinoma cell line.41 Whether inhi-
bition of the PI3K/AKT/mTOR pathway would restore sensi-
tivity to these crizotinib-resistant tumors is yet to be shown.
Amplification of MET, which encodes the hepatocyte 
growth factor receptor, has been observed in NSCLC.42–44 
MET amplification leads to erythroblastic leukemia viral 
oncogene homolog 3 phosphorylation and subsequent PI3K/
AKT/mTOR activation. Thus, EGFR-TKI–resistant tumors 
with MET amplification achieve erythroblastic leukemia viral 
oncogene homolog 3 phosphorylation despite the inhibition 
of EGFR.29 In preclinical models, inhibition of MET can 
restore sensitivity to the EGFR-TKI. For example, sensitiv-
ity to EGFR-TKIs has been restored using the dual PI3K/
mTOR inhibitor PI-103, providing the proof of concept that 
dual inhibition of EGFR and the PI3K/AKT/mTOR pathway 
can overcome resistance to EGFR-TKIs in NSCLC.32
Mutations in PI3K/AKT/mTOR Pathway 
Components
Supporting the central role of the PI3K/AKT/mTOR path-
way, mutations that cause aberrant pathway activation are com-
monly observed in cancers.8,12,13 For this reason, there has been 
great interest in understanding these mutations and in the effect 
of pathway-specific inhibitors on tumors with these mutations.
The loss or reduction of tumor-suppressor PTEN expres-
sion is observed in 30% to 70% of NSCLC.22,45 As a negative 
regulator, the absence of PTEN leads to unrestricted PI3K/
AKT/mTOR pathway activation, suggesting a role for pathway-
specific inhibitors in the treatment of tumors with reduced or 
absent PTEN expression. For example, the dual PI3K/mTOR 
inhibitor PF-04691502 demonstrated antitumor activity in 
PTEN-null EGFR-TKI–resistant NSCLC tumor xenografts.46 
This targeted approach is also being explored in some ongoing 
studies that are testing PI3K/AKT/mTOR pathway inhibitors in 
patients with a PTEN mutation or low or null PTEN expression.
Mutations and amplifications of PIK3CA, the gene 
encoding the main catalytic subunit of PI3K, can cause 
ligand-independent activation of the PI3K/AKT/mTOR path-
way, increasing the oncogenic potential of the mutant cell(s).47 
Furthermore, the presence of PIK3CA mutations in advanced 
NSCLC tumors has also been found to portend a shorter 
median time to progression and decreased median overall sur-
vival.48 In EGFR-TKI–resistant NSCLC xenografts harboring 
a mutated PIK3CA gene, PF-04691502 administration induced 
antitumor activity.46 A second dual PI3K/mTOR inhibitor led 
to marked tumor regression in a lung adenocarcinoma tumor 
model driven by a mutated PIK3CA gene.49 Combined, these 
results suggest a role for PI3K/AKT/mTOR inhibitors in the 
treatment of PIK3CA-mutated tumors—a hypothesis being 
tested in ongoing clinical studies (see below).
The liver kinase B1 (LKB1) kinase is involved in metab-
olism homeostasis and suppresses cell growth activation of 5′ 
adenosine monophosphate-activated protein kinase (AMPK) 
kinases when nutrient levels are depleted.50 LKB1 mutant cells 
lack AMPK activity, are refractory to mTOR inhibition a glucose 
depletion, and are less resistant to cell death upon glucose depriva-
tion than are wild-type cells.51 Interestingly, KRAS mutations are 
commonly associated with LKB1 mutations, suggesting a role for 
RAS/RAF/MEK signaling in the control of mTOR activation.52,53 
Therefore, to avoid cross-talk, inhibition of both pathways may be 
optimal. This hypothesis is supported by the reduced proliferation 
observed in LKB1/KRAS-mutated NSCLC cell lines treated con-
currently with MEK and mTOR inhibitors.52 In addition, the pan 
PI3K inhibitors SAR245408 (XL147) and PX-866 inhibited PI3K 
signaling and led to antitumor activity in KRAS-activated and 
LKB1-deficient A549 adenocarcinoma xenografts (Table 2).35,54
The glutamic acid to lysine mutation at codon 17 in 
AKT1, although rare, leads to constitutive kinase activity.55 As 
an important central node of the PI3K/AKT/mTOR pathway, 
this causes ligand-independent signaling. AKT inhibitors and 
PI3K/AKT/mTOR inhibitors that target downstream of AKT 
(i.e., mTORC1 inhibitors and dual PI3K/mTOR inhibitors) 
may be useful in this context. This concept is being explored 
in an ongoing trial in which patients with mutated AKT1 are 
being treated with the AKT inhibitor MK-2206.
Mutations in RAS/RAF/MEK Pathway 
Components
PI3K/AKT/mTOR pathway activation can also be a 
result of signaling from parallel pathways. For example, 
KRAS activation of the RAS/RAF/MEK pathway can lead 
to cross-talk through PI3K. Thus PI3K/AKT/mTOR pathway 
inhibitors could also help overcome the challenge of activat-
ing mutations in parallel pathways.
Mutations in the guanine triphosphatease KRAS induce 
a constitutively active state, allowing for signaling in the 
absence of RTK activation.56 In addition to activating the RAS/
RAF/MEK pathway, mutated KRAS can also activate the par-
allel PI3K/AKT/mTOR pathway.57 Targeting KRAS-driven 
tumors with the single-agent PI3K/AKT/mTOR pathway 
inhibitors ridaforolimus (formerly deforolimus) (an mTORC1 
inhibitor) or SAR245408 (a dual PI3K/mTOR inhibitor) has 
shown preclinical activity in NSCLC xenograft models.58,59 
However, as described below, a more robust attenuation of 
aberrant pathway activation may be better achieved with inhi-
bition of multiple pathways.
KRAS mutations correlate with resistance to EGFR-based 
therapies,25 and the presence of both KRAS and PIK3CA muta-
tions may be associated with resistance to PI3K/AKT/mTOR 
1319Copyright © 2012 by the International Association for the Study of Lung Cancer
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pathway inhibitors.60 The RAF and MEK kinases are down-
stream of KRAS, and inhibitors to these targets may attenu-
ate the continuous signaling of activated KRAS. Indeed, MEK 
and PI3K inhibitors (ARRY-142886 and BEZ235, respectively) 
alone did not inhibit KRAS-driven lung tumor mouse models, 
but the combination did.49 Therefore, targeting the RAF/MEK/
extracellular signal-regulated kinase and PI3K/AKT/mTOR 
pathways may help overcome resistance in KRAS-driven 
tumors. This concept is now being explored in clinical trials.
NOVEL AGENTS TARGETING THE PI3K/AKT/
mTOR PATHWAY IN NSCLC PATIENTS
Agents targeting the PI3K/AKT/mTOR pathway are 
being explored in lung cancer and advanced solid tumors 
TABLE 2.  Novel Agents Targeting the PI3K/AKT/mTOR Pathway in Lung Cancera
Agent Company
Development 
Phase Administration Dose-Limiting Toxicities Reference
Pan-PI3K inhibitors
 BAY-80–6946 Bayer I IV (3 weekly doses 
every 4 weeks)
Acute left ventricular dysfunction, lactic 
acidosis, liver dysfunction, renal 
insufficiency, hyperglycemia
75
 BKM120 Novartis II Oral, QD Hyperglycemia, epigastralgia, skin rash, 
mood alteration
63
 GDC-0941 Genentech/Piramed I Oral, QD/BID(twice 
a day/two times per 
day/twice daily)
Macular rash, asymptomatic T-wave 
inversion, thrombocytopenia, 
hyperglycemia
71
 PX-866 Oncothyreon II Oral, QD Diarrhea, ALT/AST elevation 69
 SAR245408 
(XL147)
Sanofi-aventis/ 
Exelixis
II Oral, QD Rash 65
Dual PI3K/mTOR inhibitors
 BEZ235 Novartis II Oral, QD Fatigue/asthenia, thrombocytopenia 62
 GDC-0980 Genentech I Oral, QD Maculopapular rash, symptomatic 
hyperglycemia
84
 GSK2126458 GlaxoSmithKline I Oral, QD Diarrhea 141
 SAR245409 
(XL765)
Sanofi-aventis/ 
Exelixis
II Oral, BID Rash, vomiting, hypophosphatemia, 
anorexia, nausea, diarrhea, 
transaminase elevation, fatigue, 
dyskinesia, asymptomatic T-wave 
inversion
81
mTORC1 inhibitors
 Everolimus 
(RAD001)
Novartis Approved Oral, QD Stomatitis, neutropenia, hyperglycemia 142
 Temsirolimus  
(CCI-779)
Pfizer Approved IV (QD for 5 days every 
2 weeks, weekly), oral 
(QD for 5 days every 
2 weeks)
Thrombocytopenia, manic-depressive 
syndrome, stomatitis, astheniab
Vomiting, diarrhea, asthenia, 
elevated transaminases, stomatitis, 
hypocalcemia, hyperglycemiab
Elevated aminotransferases, rashc
100,143,144
Ridaforolimus 
(deforolimus, 
AP 23573, MK-
8669)
Merck/Ariad III Oral, QD Mucositis 145
Dual mTORC1/mTORC2 inhibitors
 OSI-027 OSI Pharmaceuticals I Oral, QD, QW, QD for 3 
days every week
Fatigue, decreased left ventricular 
ejection fraction
106
AKT inhibitors
 GDC-0068 Genentech/Array 
BioPharma
I Oral, QD Not reported 146
 GSK2141795 GlaxoSmithKline I Oral, QD Hyperglycemia, hypoglycemia, stomatitis 93
 MK-2206 Merck II Oral, QOD, QW Rash, mucositis 91
 Perifosine 
(KRX-0401, 
NSC 639966)
Keryx III Oral, QD Nausea, diarrhea, dehydration, fatigue, 
elevated γ-glutamyltransferase
147
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; IV, intravenous, QD, once daily; QW, once weekly; PI3K, phosphatidylinositol 3-kinase; QOD, 
evaluating alternate day.
aDose-limiting toxicities obtained from reports of single-agent phase-I dose-escalation trials, where available.
bIntravenous formulation.
cOral formulation.
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(Table 2). Because the pathway regulates multiple cellular 
processes, a good understanding of the safety profile of these 
agents is important. To date, rash, hyperglycemia, and trans-
aminase elevations seem to be class effects of PI3K/AKT/
mTOR inhibition. Indeed, because PI3K/AKT/mTOR signal-
ing plays a central role in insulin signaling, pathway inhibi-
tion can lead to insulin resistance.61–63 The agents currently 
being investigated can be broken up into multiple categories, 
depending on their target(s).
Pan-PI3K Inhibitors
Pan-PI3K inhibitors target the catalytic domain of the 
class IA PI3K p110 subunits, the class most widely impli-
cated in cancer. Targeted inhibition of this class may allow for 
anticancer activity without excessive toxicity brought about 
by inhibition of the other PI3K classes that are involved in 
other key cellular processes. Agents in this category that have 
been explored preclinically or clinically in lung cancer include 
BKM120, SAR245408 (XL147), PX-866, GDC-0941, and 
BAY-80–6946. Of note, p110 isoform-specific inhibitors are 
also being developed, but to date, most data pertaining to this 
have been limited to hematologic malignancies.
BKM120 (Novartis) is a highly specific oral pan-class 
I PI3K inhibitor with activity against the most common 
PIK3CA mutations (H1047R and E545K).64 In a recent phase 
I study, once-daily BKM120 resulted in partial responses in 
two patients with breast cancer; minor responses in patients 
with breast cancer, colon cancer, angiosarcoma, and lung 
cancer; and disease stabilization in 26 of 45 patients.63 Dose-
limiting toxicities (DLTs) included hyperglycemia, upper 
abdominal pain, skin rash, and mood alteration. BKM120 
is currently being evaluated as a single agent in a phase II 
study in patients with metastatic NSCLC and in combination 
with the MEK inhibitor GSK1120212 in a phase I study in 
advanced solid tumors.
Another oral pan-PI3K inhibitor, SAR245408 (Sanofi-
aventis, XL147, and Exelixis), has demonstrated preclinical 
activity in a variety of mouse xenograft models, including 
the KRAS-activated A549 and Calu-6 NSCLC models as a 
single agent or in combination with chemotherapy (pacli-
taxel or carboplatin), rapamycin, or an EGFR inhibitor.54,59 In 
a phase I study in advanced solid tumors, XL147 treatment 
led to prolonged disease stabilization in nine of 68 patients 
and to a partial response in one patient with NSCLC.65 The 
only DLTs reported were grade 3 skin rashes. This agent is 
currently being explored, and has promising activity in com-
bination with erlotinib or paclitaxel and carboplatin in patients 
with NSCLC.66,67
The wortmannin derivative PX-866 (Oncothyreon) is an 
oral irreversible class IA and IB PI3K inhibitor with demon-
strated in vivo antitumor activity against A549 lung adeno-
carcinoma xenografts that express activated KRAS and are 
deficient in the tumor-suppressor LKB1—a negative regu-
lator of the PI3K/AKT/mTOR pathway.35,68 Final data from 
a phase I study testing single-agent PX-866 in heavily pre-
treated patients with advanced solid tumors showed disease 
stabilization in seven of 31 evaluable patients, including one 
patient with NSCLC.69 DLTs included diarrhea and elevated 
liver enzyme levels. A study testing PX-866 in combination 
with docetaxel is currently recruiting patients with NSCLC 
and SCC of the head and neck.
GDC-0941 (Genentech) is a selective and potent, orally 
bioavailable inhibitor of class-I PI3Ks that binds competitively 
to the adenosine-5′-triphosphate (ATP) binding site of PI3K.70 
Evidence of biologic activity was reported in two phase I studies 
testing single-agent GDC-0449 in advanced solid tumors or mul-
tiple myeloma.71,72 DLTs from both studies included headache, 
pleural effusion, decreased diffusing capacity of the lung for 
carbon monoxide, asymptomatic T-wave inversion on electrocar-
diogram, thrombocytopenia, hyperglycemia, and maculopapular 
rash. A recent report from a phase I clinical trial testing GDC-
0941 in combination with the MEK inhibitor GDC-0973 showed 
encouraging activity in patients with melanoma, prostate cancer, 
and NSCLC.73 In addition, a trial evaluating GDC-0941 in com-
bination with paclitaxel and carboplatin, with or without bevaci-
zumab, in patients with NSCLC is ongoing.74 Partial responses 
were observed in eight of 18 patients, and grade 3/4 neutropenia 
has been the most severe treatment-related adverse event to date.
TABLE 3.  Definitions
Acronym Definition
PI3K Phosphatidylinositol 3-kinase
mTOR Mammalian target of rapamycin
RTK Receptor tyrosine kinase
HER2 Human epidermal growth factor receptor 2
EGFR Epidermal growth factor receptor
ALK Anaplastic lymphoma kinase
IGFR Insulin-like growth factor receptor
VEGFR Vascular endothelial growth factor receptor
PDGFR Platelet-derived growth factor receptor
SHIP Src homology 2 domain-containing inositol 5´-phosphatase
PTEN Phosphatase and tensin homolog
PIP
2
Phosphatidylinositol 4,5-bisphosphate
PIP
3
Phosphatidylinositol 3,4,5-triphosphate
PDK1 3-phosphoinositide-dependent kinase 1
mTORC2 mTOR complex 2
TSC2 Tuberous sclerosis 2
MDM2 Minute double minute 2
FOXO Forkhead box O
BAD Bcl-2–associated death promoter
INPP4B Inositol polyphosphate-4-phosphatase, type II
IRS1 Insulin receptor substrate 1
RAS Rat Sarcoma
EML4 Echinoderm microtubule-associated protein-like 4
MET Mesenchymal epithelial transition factor
ERBB3 Erythroblastic leukemia viral oncogene homolog 3
LKB1 Liver kinase b1
MEK Mitogen-activated protein kinase or Erk kinase
GTP Guanine triphosphate
PKC Protein kinase C
PKA Protein kinase A
SGK Serum and glucocorticoid-induced protein kinase
Stat3 Signal transducer and activator of transcription 3
ERK1/2 Extracellular signal-regulated kinase 1/2
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Unlike the aforementioned agents, which are being 
developed as oral formulations, BAY-80–6946, a potent and 
selective reversible class-I PI3K inhibitor, is being tested as 
a weekly intravenous infusion for 3 weeks every 28 days. In 
a phase I dose-escalation study, a 40% reduction in fluorode-
oxyglucose uptake was observed in an NSCLC lesion.75
Dual PI3K/mTORC1/2 Inhibitors
The catalytic domains of the p110 subunits and mTOR1/2 
share a structural homology. Therefore, some small-molecule 
inhibitors are able to target both protein families. Agents in 
this class—including BEZ235, SAR245409 (XL765), GDC-
0980, and GSK2126458—may offer an advantage by target-
ing multiple points within the PI3K/AKT/mTOR pathway, 
thereby creating a more effective pathway inhibition. Of 
course, the greater number of targets also increases the poten-
tial for increased toxicity, something that must be balanced 
with respect to the potential gain in efficacy.
BEZ235 (Novartis), an oral imidazoquinoline deriva-
tive with potent inhibitory activity against PI3K and mTOR, 
also blocks vascular endothelial growth factor-induced angio-
genesis and tumor vascular permeability. BEZ235 has shown 
potent growth-inhibitory effects, with lethality observed in the 
presence or absence of PI3K or PTEN mutations.76 BEZ235 
has also been shown to reduce AKT phosphorylation and 
S6 expression in the lung cancer cell lines epidermoid lung 
cancer, Hamon Cancer Center, and H1339, and mouse lung 
adenocarcinomas driven by p110 showed marked tumor 
regression after treatment with BEZ235.49,77 Of note, tumors 
driven by mutant KRAS did not respond with BEZ235 treat-
ment alone, but did exhibit marked synergy with an MEK 
inhibitor (ARRY-142886) to shrink these KRAS-mutant 
tumors.49 Interestingly, although BEZ235 inhibits PI3K p110 
subunits and mTORC1/2, synergistic effects in growth inhi-
bition of NSCLC cells and tumor xenografts were observed 
when BEZ235 was used in combination with the mTORC1 
inhibitor everolimus.78 This has been hypothesized as a result 
of enhanced cell-cycle arrest and induction of apoptosis, and 
highlights the role of enhanced PI3K/AKT/mTOR inactiva-
tion in cancer treatment.
A phase I trial testing single-agent BEZ235 showed 
promising early efficacy in 51 patients, with two partial 
responses (one patient with Cowden syndrome and one patient 
with breast cancer), 16 minor responses, and 14 cases of dis-
ease stabilization.79 Frequently reported mild-to-moderate 
adverse events included nausea, vomiting, diarrhea, fatigue, 
anemia, and anorexia. A new formulation of BEZ235 with 
improved bioavailability and pharmacokinetic properties was 
well tolerated in a phase I study in patients with advanced 
solid tumors and will be used in a phase II study in solid tumor 
patients with alterations in the PI3K pathway.62
SAR245409 (Sanofi-aventis, XL765, and Exelixis), a 
potent and specific reversible ATP-competitive dual inhibi-
tor of class-I PI3K isoforms and mTOR, significantly slowed 
tumor growth or caused tumor shrinkage in xenograft models 
(including lung). Furthermore, XL765 inhibited tumor cell 
proliferation and angiogenesis, induced apoptosis, and led 
to substantial tumor regression after cessation of dosing in 
an NSCLC xenograft model.80 In a phase I trial testing oral 
XL765 in patients with advanced malignancies, pharmacody-
namic modulation of PI3K signaling as evidenced by post-
dose reductions in p-AKT-T308 was evident in paired tumor 
biopsies and surrogate tissues.81 Disease stabilization and pro-
longed disease stabilization were noted in 11 and seven of 79 
patients, respectively. Common drug-related adverse events 
included nausea, diarrhea, anorexia, elevated liver enzyme 
levels (four patients with grade 3/4 events), skin disorders, 
and vomiting. In a combination study testing XL765 and erlo-
tinib, prolonged disease stabilization was observed in four of 
13 patients with NSCLC refractory to anti-EGFR therapy.82 
Grade 1/2 diarrhea and skin disorders were the most common 
treatment-related adverse events.
GDC-0980 (Genentech) and GSK2126458 (Glaxo 
SmithKline), dual inhibitors of class-I PI3K and mTOR, are 
also being evaluated in clinical trials in patients with advanced 
solid tumors. Preliminary data from a first-in-human phase-I 
study testing single-agent GDC-0980 showed evidence of 
antitumor activity in three patients with mesothelioma, in one 
patient with soft-tissue sarcoma, and in one patient with a gas-
trointestinal stromal tumor.83,84 Maculopapular rash and hyper-
glycemia are the only DLTs reported to date. GDC-0980 also 
has a phase-I study planned, in combination with carboplatin 
and paclitaxel, with or without bevacizumab. GSK2126458 is 
currently undergoing a dose-escalation study and a combina-
tion trial with the MEK inhibitor GSK1120212.
AKT Inhibitors
The development of AKT inhibitors was initially hin-
dered by the high degree of homology in the ATP-binding 
pocket between AKT, protein kinase A, and protein kinase C. 
However, novel agents that target the serine/threonine kinase 
AKT, either competing for the ATP-binding site (i.e., GDC-
0068) or acting elsewhere within the protein, have recently 
been developed. For example, perifosine and MK-2206 target 
regions in or near the pleckstrin homology domain of AKT, 
which prevents AKT translocation to the plasma membrane. 
This keeps AKT inactive and renders it unable to activate the 
downstream targets that drive cell growth, metabolism, sur-
vival, and proliferation.85,86
Some AKT inhibitors are isozyme specific and others 
target multiple AKTs. Because the roles of each AKT mem-
ber are not fully understood, it is unknown which type of 
AKT inhibitor will be most successful. Despite encouraging 
preclinical data in NSCLC cells, nonspecific AKT inhibitors 
such as perifosine have shown disappointing activity in solid 
tumors. Triciribine (API-2)—a reversible tricyclic nucleoside 
that selectively inhibits the cellular phosphorylation and acti-
vation of AKT1/2/3 with minor effects on cellular signaling 
mediated by protein kinase C, protein kinase A, serum and 
glucocorticoid-induced protein kinase, signal transducer and 
activator of transcription 3, p38, extracellular signal-regulated 
kinase 1/2—has demonstrated limited efficacy despite severe 
hyperglycemia, hypertriglyceridemia, hepatotoxicity, mucosi-
tis, and fatigue.87 Furthermore, in a phase II trial, no responses 
were observed in the 12 patients with advanced NSCLC, sug-
gesting that triciribine is not active in NSCLC.88
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MK-2206 (Merck) is a first-in-class allosteric 
AKT1/2/3 inhibitor with evidence of preclinical activ-
ity and demonstrates synergistic activity in combination 
with cytotoxic agents (doxorubicin, gemcitabine, docetaxel, 
and carboplatin) in lung NCI-H460 cells. Furthermore, 
MK-2206 suppresses AKT phosphorylation induced by 
carboplatin and gemcitabine, which may improve the effi-
cacy of these agents by suppressing activation of this 
cell-survival pathway.89 MK-2206 has also been shown to 
enhance erlotinib activity in erlotinib-sensitive and -resistant 
NSCLC cell lines and to resensitize cells rendered resistant 
through c-MET activation by hepatocyte growth factor.90 
In a phase I study, single-agent MK-2206 caused tumor 
regressions in a patient with pancreatic cancer with loss of 
PTEN expression, and caused minor tumor regressions in one 
patient with melanoma and in one patient with a neuroendo-
crine tumor.91 Anti-angiogenic activity was seen in 18 of 23 
evaluable patients in the form of a post-treatment decline in 
circulating endothelial cells. Common reversible drug-related 
toxicities included rash, nausea, fatigue, and hyperglycemia. 
MK-2206 is also undergoing evaluation in combination with 
chemotherapeutic agents and anti-HER2 therapy in breast 
cancer patients. In addition, on the basis of the preclinical 
rationale, the combination of MK-2206 and the MEK inhibi-
tor AZD6244 (AstraZeneca) has been investigated and has 
shown encouraging activity, notably in NSCLC.92
Other oral AKT inhibitors in phase I trials in 
cancer patients include GSK2141795, GSK2110183 
(GlaxoSmithKline), GDC-0068 (Genentech), and LY2780301 
(Eli Lilly and Co.), which also inhibits p70 S6 kinase. 
GSK2141795 was recently reported to demonstrate activity in 
anal, endometrial, and prostate cancers with reversible hyper-
glycemia, hypoglycemia, and stomatitis being the DLTs.93
mTORC1 Inhibitors
The most developed class of PI3K/AKT/mTOR path-
way inhibitors are those that target mTORC1. These include 
everolimus, temsirolimus, and ridaforolimus. Both everolimus 
and temsirolimus have been approved by the Food and Drug 
Administration for renal cell carcinoma, and everolimus has 
also been approved for subependymal giant-cell astrocytoma 
associated with tuberous sclerosis and neuroendocrine tumors 
of pancreatic origin. Ridaforolimus is currently in a phase III 
study of sarcoma.
Everolimus has been studied in multiple clinical trials in 
patients with NSCLC. Because single-agent activity has been 
relatively modest,94 trials have focused on finding effective 
combination chemotherapies and targeted agents. However, 
to date, results of phase II combination studies have shown 
limited activity in NSCLC patients. For example, the response 
rate for the combination of everolimus and gefitinib was 13% 
(all partial response) in patients with advanced NSCLC who 
had either received no prior chemotherapy or had been previ-
ously treated with cisplatin or carboplatin and docetaxel or 
pemetrexed.95 Similarly, only two patients (7%) achieved a par-
tial response when everolimus was given in combination with 
docetaxel as a second- or third-line treatment.96 Combination 
therapy with erlotinib has also been explored; the results 
are encouraging but do not indicate definitive superiority to 
single-agent therapy.97 Many combination trials are ongoing, 
with the hope of finding effective treatment partners.
In preclinical studies, temsirolimus suppressed the pro-
liferation of NSCLC cell lines (A549, H1299, and H358) in 
a dose-dependent manner that was accompanied by inhibition 
of mTOR phosphorylation. In addition, temsirolimus induced 
significant reductions in mouse NSCLC xenografts and pro-
longed survival in a pleural disseminated tumor-bearing mouse 
model.98 Activity has also been observed in combination with 
docetaxel in adenocarcinoma NSCLC cells.99 Clinically, a 
patient with NSCLC achieved a partial response lasting for 
12.7 months in a phase I study in patients with advanced solid 
tumors.100 In a phase II study in patients with small-cell lung 
cancer temsirolimus was administered as maintenance therapy 
after stable disease, or in patients with disease that responded 
to induction therapy with cisplatin or carboplatin plus etopo-
side or irinotecan. In this study, temsirolimus did not seem to 
increase progression-free survival in these patients.101 Clinical 
trials with other combination partners are ongoing.
Ridaforolimus was previously shown to inhibit NSCLC 
cell lines, including those that harbor KRAS mutations. 
Ridaforolimus also inhibited the growth of erlotinib-resistant, 
KRAS-mutant NSCLC xenograft models, and the combina-
tion of ridaforolimus and erlotinib had benefit over single-
agent therapy.58 Published data from clinical studies with 
ridaforolimus in lung cancer are limited to a single patient 
achieving a partial response in a phase I dose-escalation trial 
in patients with advanced solid tumors.102 Ongoing studies 
include a phase I combination trial with cetuximab in patients 
with head and neck cancer or NSCLC and a phase II trial in 
NSCLC patients with KRAS mutations.
These agents, synthetic derivatives of rapamycin with 
improved pharmacokinetic properties, predominantly inhibit 
mTORC1, which could leave mTORC2 capable of activating 
AKT. Furthermore, inhibition of mTORC1 alone may uncou-
ple the feedback inhibition governed by S6K-insulin receptor 
substrate 1-PI3K, which could further increase AKT activa-
tion.11 Thus, these agents may be best used in combination 
with other PI3K/AKT/mTOR pathway inhibitors to maxi-
mize pathway inactivation. In addition, everolimus can cause 
extracellular signal-regulated kinase pathway reactivation in a 
PI3K-dependent manner.103 Together, these data suggest that 
pathway activation and reactivation could be avoided by PI3K, 
AKT, or concomitant PI3K and mTOR catalytic inhibition 
(which would target both mTORC1 and mTORC2).
Dual mTORC1/mTORC2 Inhibitors
Development of ATP-competitive catalytic site inhibi-
tors of the mTOR kinase that inhibits the function of both 
mTORC1 and mTORC2 is ongoing.104 On the basis of prom-
ising preclinical data, the mTORC1/2 inhibitors INK128 
(Intellikine), AZD8055 (AstraZeneca), and OSI-027 (OSI 
Pharmaceuticals) are entering early clinical trials.105,106 A 
phase I trial with OSI-027 reported disease stabilization in 
eight of 31 treated patients, and fatigue and a decrease in left 
ventricular ejection fraction as DLTs.106
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Molecular mechanisms responsible for differences in 
sensitivity to mTOR inhibition have not been clearly elucidated. 
Understanding how these agents affect the PI3K/AKT/mTOR 
pathway in the clinical setting is of great interest, and many of 
the ongoing clinical trials are now analyzing tumor samples and 
other biomarkers to better discern a connection between path-
way inhibition and efficacy and safety profiles. Furthermore, 
molecular profiling is being used in some trials to focus on the 
effect of these novel agents in patients with activated PI3K/
AKT/mTOR pathways (see below). The results of these studies 
are of particular interest in the field of personalized medicine.
CLINICAL DEVELOPMENT OF PI3K/AKT/mTOR 
PATHWAY INHIBITORS
In clinical studies of single-agent PI3K/AKT/mTOR 
pathway inhibitors reported to date, only a few partial 
responses have been reported, and the most common best 
response is stable disease. However, it should be noted that 
most of these were phase I studies that did not select patients 
with an activated PI3K/AKT/mTOR pathway. Thus, it is diffi-
cult to gauge the role of these agents in a personalized-therapy 
setting in these trials.
Screening and treating NSCLC patients with mutation-spe-
cific agents have shown recent success.107–109 Given the improve-
ments in identifying mutations and the target-specific agents being 
explored, this individualized therapy approach holds great prom-
ise, and mutation detection is becoming increasingly important in 
clinical trials. Indeed, whereas many studies examine mutational 
status retrospectively, some trials of PI3K/AKT/mTOR pathway 
inhibitors are incorporating a prospective screening process for 
pathway mutations. For example, in a phase I study of BEZ235 
(NCT01195376), the inclusion criteria require patients with 
advanced solid tumors to have a PIK3CA mutation (or amplifica-
tion) and/or a PTEN mutation and/or low or null PTEN expres-
sion. In studies of ridaforolimus (NCT00818675) and MK-2206 
(NCT01021748), patients are required to have KRAS-driven 
NSCLC. In a study sponsored by the National Cancer Institute 
(NCT01306045), patients with lung cancer are prescreened and 
allocated into treatment groups based on the molecular profiles of 
their tumor biopsies. One of the arms of this study is investigat-
ing MK-2206, which will be used to treat patients with PIK3CA, 
AKT, or PTEN gene mutations. MK-2206 is also being studied 
in a similar study—the Biomarkers-Integrated Approaches of 
Targeted Therapy for Lung Cancer Elimination-2 (BATTLE-2; 
NCT01248247). The results of these studies should help to better 
identify patients who will best be suited for treatment with agents 
that target the PI3K/AKT/mTOR pathway.
The cytostatic effects of these compounds suggest that 
efficacy may be best achieved when the PI3K/AKT/mTOR 
inhibitors are used in combination with cytotoxic agents. This 
could be achieved by targeting multiple oncogenic pathways in 
an effort to target the tumor and its potential survival pathways. 
In this scenario, treatment with a PI3K/AKT/mTOR inhibi-
tor could reduce the possibility of tumor resistance through 
escape pathways, thereby extending the amount of time during 
which a patient receives benefit from the combination part-
ner. This approach could also reduce the psychological and 
toxicological impact on the patient and minimize the potential 
cross-reactivity of subsequent treatment regimens.
PI3K/AKT/mTOR pathway inhibitors may also offer 
the added benefit of restoring sensitivity to anticancer agents 
to which the tumor has become resistant. Indeed, mutations 
in the PI3K/AKT/mTOR pathway negatively affect the effec-
tiveness of therapies targeting upstream components. In this 
setting, resistance to agents used to target proteins at the apex 
of the pathway may be a result of these downstream PI3K/
AKT/mTOR pathway mutations, which promote cell survival. 
Therefore, targeting the PI3K/AKT/mTOR pathway may over-
come this resistance and restore sensitivity to agents that are 
well tolerated, thereby providing clinical benefit.32–34,110
SUMMARY
Targeting a patient’s tumor with the most effective anti-
cancer agent(s) for that tumor is a key step toward person-
alized medicine. Clear identification and targeted treatment 
of the molecular characteristics that make up and drive the 
tumor are important steps in this process. For tumors with an 
activated PI3K/AKT/mTOR pathway, targeted agents can not 
only impact tumor survival, but restore sensitivity to agents 
that were well tolerated and provided clinical benefit.
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